Browse the evidence

An exploratory every-8-weeks regimen showed attenuated efficacy compared to once-monthly dosing.

Practitioners should consider monthly dosing as more effective than less frequent regimens.

Gut-derived hormones, the central nervous system, and pancreatic function interact to maintain energy homeostasis.

Understanding the interplay of these systems can inform strategies for addressing metabolic disorders.

Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections.

Clinicians should be aware of the higher incidence of adverse events with semaglutide.

The benefits of GLP-1R agonists may be enhanced by stimulating other receptors.

Combining GLP-1R agonists with other receptor agonists may enhance therapeutic outcomes.

Maximal and sustained benefit of GLP-1 receptor agonists may be compromised by poor compliance and cessation of use.

Practitioners should address compliance issues when prescribing GLP-1 receptor agonists.

GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038).

Practitioners should monitor cardiovascular health in patients using GLP-1 RAs.

The Deep Reinforcement Learning (DRL) agent decreased gastrointestinal (GI) adverse events incidence by 35% and severity by 42% in simulations.

Implementing a DRL agent for dosing may significantly reduce GI side effects in patients.

Medication adherence increased from 52.8% to 84%.

Encouraging medication adherence can significantly improve patient outcomes.

In women, an ILI-associated decrease in estradiol of 14% from baseline to year 1 mediated a decline in whole-body BMD of -1.15 mg/cm2.

Practitioners should consider the hormonal changes in postmenopausal women when implementing weight loss interventions.

In men, an ILI-associated increase of 11% in total testosterone mediated a decline of hip BMD of -1.18 mg/cm2.

Practitioners should consider the hormonal changes in older men when implementing weight loss interventions.

ILI-associated changes in estradiol and total testosterone resulted in whole-body and hip bone loss.

Weight loss interventions may lead to hormonal changes that affect bone health in older adults.

Rare deleterious variants in six specific effector genes (MC4R, PCSK1, POMC, CALCR, BSN, and CORO1A) are significantly associated with BMI at the population level, with CORO1A being a newly identified genetic risk factor for obesity.

Genetic testing can identify individuals with rare variants in genes like CORO1A, MC4R, or PCSK1 who are at higher risk for severe obesity. Knowing this early can guide personalized prevention strategies, such as early lifestyle interventions or targeted pharmacological therapies, before significant weight gain occurs.

Existing FDA-approved smoking cessation medications (varenicline, nicotine replacement therapy, and bupropion alone) provide only modest attenuation of post-cessation weight gain and do not eliminate it.

Standard smoking cessation drugs like patches, gum, or varenicline will help you quit, but they are not designed to stop you from gaining weight afterward. Expect modest weight changes, but do not rely on them to maintain your weight.

Obesity is a biologic disorder caused by alterations in CNS pathways controlling energy balance, not a lifestyle failure remediable by willpower alone.

Stop blaming yourself for your weight. Your body is fighting you due to biological mechanisms, not just willpower. Seek medical treatment for obesity just as you would for high blood pressure.

GLP-1 therapy is associated with significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) which are dose-dependent and can lead to discontinuation, although most side effects decrease with continued use.

You will likely experience some gastrointestinal side effects like nausea, diarrhea, or constipation, especially when you start the medication or increase the dose. These symptoms often improve over time. Talk to your doctor about managing these side effects through diet and slow dose titration.

Obesity is a chronic, progressive, relapsing, and treatable multi-factorial neurobehavioral disease, not just a lifestyle choice.

Understand that obesity is a disease with biological drivers, not just a failure of will. This reduces self-blame and opens the door to effective medical and lifestyle interventions.

SGLT2 inhibitors provide consistent cardiovascular benefits (reduced mortality and morbidity) across all BMI classes in heart failure, with no mediating effect of obesity on their efficacy.

If you have heart failure, SGLT2 inhibitors (like Dapagliflozin or Empagliflozin) are a standard, highly effective treatment that works regardless of your weight. They reduce the risk of hospitalization and death. Discuss starting these with your doctor if you are not already on them.

Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.

Genetics play a significant role in obesity risk. If you have a family history of obesity, you may have a higher predisposition. However, this does not mean weight management is impossible; tailored medical and lifestyle strategies can be highly effective.

Higher genetically predicted lifelong BMI causally increases all-cause mortality, with the effect substantially mediated through diabetes.

In this population, higher lifelong BMI significantly increases the risk of premature death, largely by increasing the risk of diabetes. Managing weight and blood sugar are critical for longevity.

Higher genetically predicted BMI causally increases the risk of renal, acute diabetic crisis, and infective deaths.

Higher BMI is strongly linked to death from kidney disease, severe diabetic episodes, and infections. Preventing these outcomes requires addressing underlying metabolic health.

Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.

If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.

Sodium glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status.

If you have HFpEF, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to reduce the risk of heart failure hospitalization and cardiovascular death, even if you do not have diabetes. They are a standard part of modern treatment.

GLP-2 analogs are effectively used in the management of short bowel syndrome, reducing the need for parenteral support and improving patient quality of life.

For patients with short bowel syndrome, GLP-2 analogs are an effective treatment that can reduce the need for intravenous nutrition (parenteral support) and improve quality of life.

Glucagon remains essential for emergency hypoglycemia treatment.

Glucagon is an essential emergency treatment for severe hypoglycemia. Patients at risk should have access to glucagon kits and be trained in their use to ensure rapid and effective treatment of low blood sugar episodes.